Paul Vrenken
ESR10: In silico methods for selecting oral formulations and dosing in early clinical studies
Bayer AG, Germany (Bayer)
Supervisor: Dr. Andre Dallmann (Bayer), Dr. Maria Vertzoni (NKUA)
Planned secondments: NKUA, Greece
Project Description
My project aims to develop and evaluate PBPK models for oral immediate and enabling drug release formulations. The model input data will be obtained extrapolation of animal free in vitro experiments. These models and extrapolations, in an industrial environment, will assist in making formulation and dose selection decisions for early clinical studies.
Background
Paul Vrenken is currently a PhD candidate within the InPharma network. He received a BSc Psychobiology form the University of Amsterdam, his MSc degree in Drug Discovery & Safety was awarded by the Vrije Universiteit (Amsterdam, the Netherlands) in 2020. During his masters he specialized in drug disposition and safety assessment.
His research interest in predicting drug pharmacokinetics using in silico tools was sparked during an eight-month internship at TNO, the Dutch institute of applied sciences. Where he used data obtained from ex vivo intestinal permeability and liver perfusion experiments to inform physiologically based pharmacokinetic models.
Third and final annual InPharma Meeting took place in Odense, Denmark
Following in the footsteps of the first two very successful meetings in Cork (2022) and Athens (2023) the third and final annual InPharma meeting took place at the university of
